Pharmaceutical compositions and methods are presented for creating a ternary structure involving a fluorescent molecule, an intermediate carrier molecule, and a larger protein or polymer with a binding site receptive to the intermediate molecule or fluorescent/intermediate complex. The resulting ternary system improves the binding stability of the fluorescent dye to the protein, both in-vivo and in-vitro. This improved stability results in a longer half-life in medical use, enabling improved qualitative and quantitative use of the dye.

##STR00001##

A disposable absorbent article having a topsheet, a backsheet, and an absorbent core disposed between the topsheet and the backsheet is described. The disposable absorbent article includes an odor control composition having a preservative, a surfactant, methylated beta-cyclodextrin (m-BCD), and perfume.

A disposable absorbent article having a topsheet, a backsheet, and an absorbent core disposed between the topsheet and the backsheet is described. The disposable absorbent article includes an odor control composition having a preservative, a surfactant, methylated beta-cyclodextrin (m-BCD), and perfume.

The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

The invention provides compositions comprising cyclodextrins encapsulating a selective ATP inhibitor, as well as uses thereof.

A solution including an associative polymer, a cyclodextrin polymer, and a solvent is provided. The associative polymer is a powder in the absence of the solvent. Additionally, a method of making down an associative polymer powder to form a solution is provided. The method includes blending a mixture of the powder, a cyclodextrin polymer, and a solvent to yield the solution, wherein the powder includes particles having been dry-cut to a median particle size of from about 200 microns to about 10,000 microns. Additionally, a powder product is provided. The powder product includes from about 80 wt. % to about 99.9 wt. % associative polymer; and from about 0.1 wt. % to about 20 wt. % of a cyclodextrin polymer.

A solution including an associative polymer, a cyclodextrin polymer, and a solvent is provided. The associative polymer is a powder in the absence of the solvent. Additionally, a method of making down an associative polymer powder to form a solution is provided. The method includes blending a mixture of the powder, a cyclodextrin polymer, and a solvent to yield the solution, wherein the powder includes particles having been dry-cut to a median particle size of from about 200 microns to about 10,000 microns. Additionally, a powder product is provided. The powder product includes from about 80 wt. % to about 99.9 wt. % associative polymer; and from about 0.1 wt. % to about 20 wt. % of a cyclodextrin polymer.

A solution including an associative polymer, a cyclodextrin polymer, and a solvent is provided. The associative polymer is a powder in the absence of the solvent. Additionally, a method of making down an associative polymer powder to form a solution is provided. The method includes blending a mixture of the powder, a cyclodextrin polymer, and a solvent to yield the solution, wherein the powder includes particles having been dry-cut to a median particle size of from about 200 microns to about 10,000 microns. Additionally, a powder product is provided. The powder product includes from about 80 wt. % to about 99.9 wt. % associative polymer; and from about 0.1 wt. % to about 20 wt. % of a cyclodextrin polymer.

Disclosed herein are compositions comprising an NSAID such as meloxicam and/or rizatriptan in combination with a cyclodextrin and/or a carbonate or a bicarbonate. These compositions may be orally administered, for example, to improve the bioavailability or pharmacokinetics of the NSAID for the treatment of pain such as migraine, arthritis, and other conditions. Also disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a T.sub.max of meloxicam of 3 hours or less.

The disclosure provides a rapidly deployable nanoscale biodegradable system using hydroxypropyl beta cyclodextrin based combination product. Cyclodextrin is an amphiphilic polymer suitable to develop an agnostic barrier blocking pathogenic mi-crobes that has localized on the mucocutaneous lining of the conjunctiva, mouth and nose, lung, or gastrointestinal tract. The cyclodex-trin may bind the viral particles and/or disrupt viral entry mechanisms by removing cholesterol from viral particles to reduce infectivity. Cyclodextrins also may facilitate removal of the viral cholesterol molecules, thus rendering them less viable. Cyclodextrin activity may be further enhanced when used in combination with certain minerals and/or antioxidant compounds.